STOCK TITAN

Bicara Therapeutics (BCAX) director granted 19,475 stock options at $20.56 strike

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Bicara Therapeutics Inc. director Michael Powell received a grant of stock options as part of his compensation. The award covers 19,475 options to buy common stock at an exercise price of $20.56 per share, expiring on June 9, 2036.

The options vest upon the earlier of June 9, 2027 or the date of the next annual meeting of stockholders, conditional on his continued service. After this grant, Powell holds 19,475 derivative securities directly, reflecting a routine equity incentive rather than an open-market purchase or sale.

Positive

  • None.

Negative

  • None.
Insider POWELL MICHAEL
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 19,475 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 19,475 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 19,475 options Stock Option (Right to Buy) grant to director
Exercise price $20.56 per share Conversion or exercise price for the options
Expiration date June 9, 2036 Option term end date
Shares underlying options 19,475 shares Underlying Bicara Therapeutics common stock
Post-transaction derivative holdings 19,475 options Total stock options held following grant
Vesting date trigger Earlier of June 9, 2027 or next annual meeting Subject to continued service condition
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "20.5600""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-06-09T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting financial
"The shares underlying this stock option vest upon the earlier of"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Annual Meeting of Stockholders financial
"the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
POWELL MICHAEL

(Last)(First)(Middle)
BICARA THERAPEUTICS INC.
116 HUNTINGTON AVENUE, SUITE 703

(Street)
BOSTON MASSACHUSETTS 02116

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Bicara Therapeutics Inc. [ BCAX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$20.5606/09/2026A19,475 (1)06/09/2036Common Stock19,475$019,475D
Explanation of Responses:
1. The shares underlying this stock option vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc., subject to the Reporting Person's continued service on such vesting date.
Remarks:
/s/ Ryan Cohlhepp, Attorney-in-Fact06/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Bicara Therapeutics (BCAX) director Michael Powell report in this Form 4?

Michael Powell reported receiving a grant of stock options for 19,475 shares of Bicara Therapeutics common stock. These options are a compensation award, not an open-market trade, and give him the right to buy shares at a fixed exercise price if vesting conditions are met.

How many Bicara Therapeutics (BCAX) stock options were granted to Michael Powell?

Michael Powell was granted 19,475 stock options linked to Bicara Therapeutics common stock. All 19,475 options are shown as held following the transaction, indicating this filing records the full award rather than a partial change to an existing options position.

What is the exercise price and expiration date of Michael Powell’s BCAX options?

The stock options granted to Michael Powell have an exercise price of $20.56 per share and expire on June 9, 2036. This means he can choose to buy Bicara Therapeutics common stock at $20.56 any time after vesting and before the expiration date.

When do Michael Powell’s Bicara Therapeutics (BCAX) stock options vest?

The options vest on the earlier of June 9, 2027, or the date of the next annual meeting of stockholders. Vesting is also subject to Michael Powell’s continued service with Bicara Therapeutics through that vesting date, as disclosed in the footnote.

Is Michael Powell buying or selling Bicara Therapeutics (BCAX) shares in this Form 4?

This Form 4 shows an acquisition of stock options as a grant, not a market buy or sell of existing Bicara Therapeutics shares. The transaction is coded as a grant or award of a derivative security, with no open-market trading reported in this filing.

How is Michael Powell’s ownership reported after this BCAX stock option grant?

After the grant, Michael Powell is reported as directly holding 19,475 stock options relating to Bicara Therapeutics common stock. The filing does not show additional option exercises or share sales, so this award represents his reported derivative position in this specific Form 4.